For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Anti-obesity therapeutics are referred as the treatment that reduces and control the body weight. The obesity is rising due to the lack of physical activities, improper or lack of sleep, high calorie diet, and fast food and heredity history of the person. The ideal anti-obesity therapeutics follows mechanisms that regulate energy balance which have substantial built-in-redundancy and overlap with other physiological functions of the body.
The Anti-Obesity Therapeutics market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028.
This report elaborates the market size, market characteristics, and market growth of the Anti-Obesity Therapeutics industry, and breaks down according to the type, application, and consumption area of Anti-Obesity Therapeutics. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.
In Chapter 2.3 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Anti-Obesity Therapeutics in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
Chapter 2.5 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 6-10 consider the impact of COVID-19 on the regional economy.
Key players in the global Anti-Obesity Therapeutics market covered in Chapter 11:
FlaxoSithKline plc.
Novo Nordisk
Takeda Pharmaceutical
Vivus
BoehringerIngelheim GmbH
Bristol-Myers Squibb
Eisai Company
Norgine Pharmaceuticals Ltd.
Zafgen
Pfizer
Alizyme
Rhythm Pharmaceuticals
Shionogi USA
In Chapter 3, on the basis of types, the Anti-Obesity Therapeutics market from 2018 to 2028 is primarily split into:
Centrally Acting Anti-obesity Drugs
Peripherally Acting Anti-obesity Drugs
In Chapter 4, on the basis of applications, the Anti-Obesity Therapeutics market from 2018 to 2028 covers:
Hospital Use
Clinic Use
Household
Other
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2028) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10:
North America (Covered in Chapter 6)
United States
Canada
Mexico
Europe (Covered in Chapter 7)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8)
China
Japan
South Korea
Australia
India
Middle East and Africa (Covered in Chapter 9)
Saudi Arabia
UAE
Egypt
South Africa
South America (Covered in Chapter 10)
Brazil
Argentina
Columbia
Years considered for this report:
Historical Years: 2018-2022
Base Year: 2022
Estimated Year: 2023
Forecast Period: 2023-2028